

Filed on behalf of Dr. Reddy's Laboratories, Ltd.  
and Dr. Reddy's Laboratories, Inc.

By: Jeffery B. Arnold  
jarnold@cantorcolburn.co  
m Cantor Colburn LLP  
1180 Peachtree Street, Suite 2050 Atlanta,  
Georgia 30309 Telephone: (404) 607-9991  
Facsimile: (404) 607-9981

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

~~TEVA PHARMACEUTICALS USA, INC.,~~ DR. REDDY'S  
LABORATORIES, LTD. AND DR. REDDY'S  
LABORATORIES, INC.,

*Petitioner*  
~~v.~~ Petitione

rs, v.

MONOSOL RX, LLC, Patent Owner ~~U.S.~~

---

Patent No. 8,603,514 Issue Date: December 10, 2013 Title:  
UNIFORM FILMS FOR RAPID DISSOLVE DOSAGE  
FORM INCORPORATING TASTE-MASKING  
COMPOSITIONS *Inter Partes* Review No.  
IPR2016-XXXXX

---

~~Case IPR2016: Unassigned~~

**PETITION FOR *INTER PARTES* REVIEW OF  
U.S. PATENT NO. 8,603,514**

**PETITIONER'S EXHIBIT LIST TABLE OF CONTENTS**

	<u>Page</u>
<u>INTRODUCTION</u> .....	<u>1</u>
<u>BACKGROUND</u> .....	<u>1</u>
<u>Brief Overview of the '514 Patent</u> .....	<u>1</u>
<u>Brief Overview of the Prosecution History</u> .....	<u>1</u>
<u>GROUND FOR STANDING</u> .....	<u>8</u>
<u>MANDATORY NOTICES UNDER 37 C.F.R. §42.8</u> .....	<u>8</u>
<u>Real Party-In-Interest (§ 42.8(b)(1))</u> .....	<u>8</u>
<u>Related Proceedings (§ 42.8(b)(2))</u> .....	<u>8</u>
<u>Lead and Backup Counsel (§ 42.8(b)(3))</u> .....	<u>10</u>
<u>Service Information (§ 42.8(b)(4))</u> .....	<u>11</u>
<u>STATEMENT OF THE PRECISE RELIEF REQUESTED AND IDENTIFICATION OF THE CHALLENGE (§ 42.104(b))</u> .....	<u>11</u>
<u>LEVEL OF ORDINARY SKILL IN THE ART</u> .....	<u>12</u>
<u>THE CHALLENGED CLAIMS OF THE '514 PATENT</u> .....	<u>13</u>
<u>CLAIM CONSTRUCTION</u> .....	<u>14</u>
<u>TECHNOLOGY TUTORIAL</u> .....	<u>15</u>
<u>Polymers</u> .....	<u>15</u>
<u>Particles</u> .....	<u>18</u>
<u>Role of Viscosity</u> .....	<u>18</u>
<u>Drying of Suspensions</u> .....	<u>21</u>
<u>Role of Uniformity in Drug Formulations</u> .....	<u>22</u>

<u>Films</u>	<u>23</u>
<u>Flavoring of Pharmaceutical Formulations</u>	<u>23</u>
<u>SCOPE AND CONTENT OF THE PRIOR ART</u>	<u>24</u>
<u>WO 00/42992 (“Chen”) (Ex. 1005)</u>	<u>24</u>
<u>U.S. Patent No. 7,067,116 (“Bess”) (Ex. 1004)</u>	<u>25</u>
<u>CA 2,274,910 (“Cremer”) (Ex. 1006)</u>	<u>26</u>
<u>DETAILED EXPLANATION OF THE GROUNDS FOR UNPATENTABILITY</u>	<u>27</u>
<u>Ground 1: The Challenged Claims of the ‘514 Patent are Invalid Under 35 U.S.C. § 103(a) as Being Obvious Over Bess in View of Chen</u>	<u>27</u>
<u>Claim Chart: Bess in View of Chen</u>	<u>39</u>
<u>Ground 2: The Challenged Claims of the ‘514 Patent are Invalid Under 35 U.S.C. § 103(a) as Being Obvious Over Chen in View of Cremer</u>	<u>50</u>
<u>Claim Chart: Chen in View of Cremer</u>	<u>52</u>
<u>CONCLUSION</u>	<u>62</u>

..

## PETITIONERS' EXHIBIT LIST

<u>Exhibit No.</u>	<u>Reference</u>
<u>1001</u>	<u>U.S. Patent No. 8,603,514 (filed July 10, 2007)</u>
<u>1002</u>	<u>File History, U.S. Patent No. 8,603,514</u>
<u>1003</u>	<u>Expert Declaration of Metin Çelik, Ph.D., Relating to U.S. Patent No. 8,603,514</u>
<u>1004</u>	<u>U.S. Patent No. 7,067,116 (filed Mar. 23, 2000) (“Bess”)</u>
<u>1005</u>	<u>WO 00/42992 (published July 27, 2000) (“Chen”)</u>
<u>1006</u>	<u>CA 2,274,910 (published June 25, 1998) (“Cremer”)</u>
<u>1007</u>	<u>File History of Reexam No. 95/002,170</u>
<u>1008</u>	<u>Alfred Martin, <i>Physical Pharmacy</i> (4th ed. 1993) (“Physical Pharmacy”)</u>
<u>1009</u>	<u>[Intentionally Left Blank]</u>
<u>1010</u>	<u>Trial Transcript, <i>Reckitt Benckiser Inc. v. Watson Labs., Inc.</i>, CA No. 14-1574-RGA (Nov. 3-4, 2015) (“Trial Tr.”)</u>
<u>1011</u>	<u>U.S. Patent No. 6,221,402 (issued April 24, 2001)</u>
<u>1012</u>	<u>C.S. Fuller et al., <i>Interactions in poly(ethylene oxide)—hydroxypropyl methylcellulose blends</i>, 42 <i>Polymer</i> 9583 (2001)</u>
<u>1013</u>	<u>Leon Lachman et al, <i>The Theory and Practice of Industrial Pharmacy</i> (1986) (“The Theory and Practice of Industrial Pharmacy”)</u>
<u>1014</u>	<u>J. Thuro Carstensen, <i>Theory of Pharmaceutical Systems Volume II: Heterogenous Systems</i> (1973) (“Theory of Pharmaceutical Systems”)</u>

...

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.